European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Merck & Co. (NYSE: MRK) Delayed: 119.60 +4.12 (3.57%)
Previous Close $115.48    52 Week High $65.46 
Open $116.53    52 Week Low $47.97 
Day High $119.80    P/E 81.36 
Day Low $116.53    EPS $1.47 
Volume 11,891,051